Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ - Summit Therapeutics stock plunges after US Food and Drug Administration (FDA) rejects approval of its lung cancer drug

BUZZ - Summit Therapeutics stock plunges after US Food and Drug Administration (FDA) rejects approval of its lung cancer drug

路透社路透社2026/11/16 10:11
Show original

- ** Summit Therapeutics (SMMT.O) shares fell 21.5% in premarket trading to $11.03

** The U.S. Food and Drug Administration (FDA) rejected (link) the company’s lung cancer drug ivonescimab

** The FDA stated that, without a significant improvement in overall survival, the drug’s benefit in delaying disease progression was insufficient to support a favorable risk-benefit profile

** In a late-stage clinical trial, ivonescimab combined with chemotherapy reduced the risk of disease progression or death by 48% compared to chemotherapy alone, showing consistent efficacy in both Asian and Western patients

** The company expects to announce late-stage trial data by the end of the year from a separate study targeting another type of lung cancer patient

** Out of 18 brokerages, 12 rate the stock “buy” or higher, and 6 rate it “hold”; the median target price is $31—LSEG data

** As of the previous session close, the stock had fallen 19.1% year-to-date


(To assist non-English speakers, Reuters has automatically translated its report into several other languages. Because automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the automated translation text and provides it for reader convenience only. Reuters bears no responsibility for any harm or loss caused by use of the automated translation function.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Nvidia (NVDA.US) leads the way! The US AI 'National Team' plan emerges: Over twenty companies to receive expedited export and federal funding support

According to sources, the Trump administration plans to select more than twenty companies, including Nvidia, as "national champion enterprises" in the field of artificial intelligence (AI), aiming to support their expansion into overseas markets.

智通财经•2026/11/16 10:47
Nvidia (NVDA.US) leads the way! The US AI 'National Team' plan emerges: Over twenty companies to receive expedited export and federal funding support

Citi: Dell price target lowered to $550

格隆汇•2026/11/16 10:31